ArticleTanaffos2025
Can the Eosinophil-to-Platelet Ratio Predict Chronic Obstructive Pulmonary Disease Exacerbations and Length of Hospital Stay?
Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: An acute exacerbation of chronic obstructive pulmonary disease is a severe condition that escalates the burden on patients and the healthcare system. This study aimed to evaluate the prognostic value of the eosinophil-to-platelet ratio (EPR) in predicting COPD exacerbations and hospital admissions, with these outcomes also assessed as secondary endpoints. Materials and Methods: This cohort study was conducted from 2023 to 2025 at Masih Daneshvari Educational Hospital in Tehran, Iran, among patients with confirmed COPD exacerbation. Participants were assessed during the recovery phase after management of the acute exacerbation. Collected clinical data included the history and frequency of exacerbations in the preceding 12 months; blood test results at discharge; 90-day mortality; hospital readmission; ICU admission; and corticosteroid use within 12 months post-discharge. Data were analyzed using STATA version 17. Results: This study evaluated 249 individuals with COPD exacerbation, with a mean age of 65.66±9.17 years. In individuals with EPR≤1, the risk of experiencing more COPD exacerbations was 17% higher than in those with EPR>1 (adjusted RR=1.17, 95% CI=0.92 -1.49, P=0.195). These results were not statistically significant. In addition, in patients with EPR≤1, the risk of having a higher number of hospitalization days was 16% lower compared to those with EPR>1 (adjusted RR=0.84, 95% CI=0.72-0.98, P=0.036). EPR was not associated with ICU admission and the need for systemic corticosteroids. Conclusion: The association between lower EPR values and a higher number of exacerbations, as well as shorter hospital stays, suggests that EPR could reflect distinct exacerbation phenotypes or patterns of disease activity.
Indexed as
Identifiers
42890640PMC13672037What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.